News | FFR Technologies | October 05, 2015

Beaumont First in Michigan to Introduce Noninvasive Diagnostic Chest Pain Tool

FFR-CT technology from HeartFlow reveals 99 percent blockage in left anterior descending artery of 65-year-old patient

Beaumont Hospital Royal Oak, first in Michigan, FFR-CT, HeartFlow Inc., heart failure

Image courtesy of HeartFlow Inc.

October 5, 2015 — Beaumont Hospital - Royal Oak is the first in Michigan and one of just a handful in the United States to offer fractional flow reserve by computed tomography, also known as FFR-CT. The technology is a noninvasive, diagnostic tool recently approved by the U.S. Food and Drug Administration (FDA) and developed by HeartFlow Inc.

Heart disease is the leading killer of men and women in the United States. In 2008, the last year for which statistics are available, more than 5 million Americans required emergency center care for chest pain and more than 16 million Americans required subsequent testing, according to the American Heart Association. As a result, 1 million invasive cardiac catheterizations were performed in 2008 throughout the nation for diagnostic purposes alone.

“Up to half of all diagnostic heart catheterizations in the United States reveal no significant coronary artery disease,” says Gil Raff, M.D., director of cardiac MRI (magnetic resonance imaging) and CT at Beaumont Hospital - Royal Oak, leading the implementation of HeartFlow technology. “FFR-CT gives us the individual patient information we need without having to perform an invasive procedure. This means we are able to reduce costs, along with the risk of radiation exposure and possible patient complications.”    

HeartFlow’s FFR-CT is a Web-based software that analyzes existing coronary angiography images to provide physicians with detailed data about blood flow within the coronary arteries. It uses a standard noninvasive coronary CT angiography scan, uploaded to the cloud, and combines it with proprietary computer algorithms to create a three-dimensional model of the patient’s coronary arteries, that can determine whether any given plaque requires cardiac catheterization.  

HeartFlow enables Beaumont to take its focus on noninvasive diagnosis of heart disease a major step forward, said Beaumont Hospital – Royal Oak interventional cardiologist Justin Trivax, M.D.

“Beaumont researchers have been leading the charge in noninvasive chest pain diagnostics with coronary computed tomographic angiography, commonly referred to as CTA, for the last decade,” Trivax said. “To that end, we’ve been able to ‘rule out’ coronary artery disease for many patients who have chest pain.

“But CCTA has limited usage for certain patients and in these cases, cardiac catheterization has been the best and most accurate diagnostic tool available,” Trivax explained. “Even with newer techniques, smaller catheters and better drugs which reduce the risk of stroke and bleeding, all procedures have some inherent risk. HeartFlow FFR-CT enables us to eliminate that risk for many patients.”

It also extends the noninvasive benefit of coronary CCTA to more high-risk and complex cases, Raff said.

Trivax’s patient, Jerry Tolle, 65, of West Bloomfield was among the first to experience the new technology.

A fitness aficionado who worked out three to four times a week using free weights and cardiovascular equipment at his local gym, both Tolle and Trivax were surprised when Tolle began experiencing chest pain. 

Tolle’s disease trajectory was atypical, according to Trivax.

“Mr. Tolle underwent stress testing but the results were not definitive. The EKG portion was abnormal but the imaging portion was normal. There wasn’t enough data to proceed with an invasive procedure at that time,” Trivax said.

Even so, Tolle failed aggressive medical therapy and complained of burning in his chest after eating. CCTA was performed and HeartFlow analysis revealed that Tolle’s left anterior descending artery — commonly known as ‘the widow maker’ — was 99 percent blocked. A stent was implanted via a heart catheterization procedure and after a few weeks’ rest, Tolle has started cardiac rehabilitation, three times a week and is doing well.

“It’s good to know that had the results not indicated a blockage, an invasive procedure would not have been necessary,” Tolle said.  “I’m not totally myself yet, but I’m back to work and feeling better each day.

“In fact,” he said, “I’ll probably get bored with rehab before I’ve finished the program – it’s significantly less intense than my previous work out.” 

For more information:

Related Content

CathWorks Receives CPT Code for Non-invasive FFRangio Measurements During PCI
News | FFR Technologies | July 12, 2018
CathWorks announced the approval of a new Current Procedural Terminology (CPT) code 0523T for non-invasive, 3-D...
The ORBITA Trial showed FFR and iFR are good predictors of PCI outcomes. This was a 2018 PCR late-breaker.
News | FFR Technologies | May 29, 2018
May 29, 2018 — The first placebo-controlled trial that looked at how fractional flow reserve (FFR) and instantaneous
FAST Study Demonstrates High Diagnostic Accuracy of CAAS vFFR
Technology | FFR Technologies | May 22, 2018
Pie Medical Imaging announced that clinical data on its CAAS vFFR (Cardiovascular Angiographic Analysis Systems for...
HeartFlow FFRct Analysis Added to ITP Payment Program in the U.K.
News | FFR Technologies | April 25, 2018
HeartFlow Inc. announced that the National Health Service (NHS) England has chosen the HeartFlow FFRct (fractional flow...
Videos | FFR Technologies | March 15, 2018
An economic analysis of the DEFINE-FLAIR study comparing FFR vs. iFR, found a cost savings of nearly $900.
iFR More Cost-Effective Than FFR in PCI Guidance
News | FFR Technologies | March 12, 2018
Philips announced health economic results from the DEFINE FLAIR clinical trial comparing cost-effectiveness between...
BlueCross BlueShield Companies in Eight States Issue Positive Medical Policies for HeartFlow FFRct Analysis
News | FFR Technologies | December 28, 2017
HeartFlow Inc. announced that Health Care Service Corp. (HCSC), which operates Blue Cross and Blue Shield plans in five...
Videos | FFR Technologies | November 15, 2017
A discussion with William Fearon, M.D.
GE Healthcare and Medis Collaborate to Expand Availability of Quantitative Flow Ratio Software
News | FFR Technologies | November 10, 2017
GE Healthcare and Dutch-based cardiovascular imaging software provider Medis announced at the 2017 Transcatheter...
FAVOR II Studies Examine Diagnostic Accuracy of Quantitative Flow Ratio, FFR-Angio.
News | FFR Technologies | November 08, 2017
Investigators in the FAVOR II China and FAVOR II Europe-Japan studies recently presented their results at the 2017...
Overlay Init